Figure 3From: PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects Comparison of 0.005 nmol PK20 to other doses of peptide used in the experiment. PK20 was injected intrathecally at doses of 0.02, 0.1 and 0.5 nmol, respectively; % MPE ± SEM of six animals per group. #p < 0.05; # #p < 0.001 versus 0.02, 0.1 and 0.5 nmol PK20/rat.Back to article page